LifeHealthcare Announces the Right to Promote Spinal Allograft Biologics Range Acquired from Australian Biotechnologies
LifeHealthcare (ASX:LHC) has today acquired the rights from Point Blank Medical to promote the Australian Biotechnologies (Aus Bio) spinal allograft biologics range and entered into a non-stocking commission only ten year distribution agreement with Aus Bio commencing 1 November 2017.
The long term partnership with Aus Bio forms a key element of LifeHeathcare’s biologics strategy, complementing LifeHealthcare’s existing synthetics biologics offering and strengthening LifeHealthcare’s spine market share in Australia. Aus Bio is a leading provider of allograft biologics in Australia and the partnership with LifeHealthcare will expand market coverage for the Allovance allograft portfolio.
For further information please download PDF attached:
Download this document
